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Patients with a significant residual stenosis after throm-
bolytic therapy are believed by many to be at increased risk
for repeat ischemic events and may be candidates for
prompt angiography and revascularization . To test the
hypothesis that patients with antecedent angina (Canadian
classes I to IV, >24 h before myocardial infarction) are
more likely to have a significant residual stenosis (?60%
diameter reduction) than are those without antecedent
angina, the coronary angiograms of 82 consecutive patients
undergoing routine angiography after thrombolytic ther-
apy were reviewed . Compared with the patients without
The efficacy of thrombolytic therapy in the treatment of
acute myocardial infarction has been clearly established in
certain well defined subsets of patients . A primary concern
after thrombolysis is the incidence of coronary reocclusion
and reinfarction, which has been reported to be as high as
20% in some studies (1- ). Because the risk of reocclusion
and postinfarction ischemia is increased in the presence of a
critical residual stenosis, routine coronary angiography and
angioplasty of suitable lesions have been advocated by some
investigators (2,3,5) . Although this approach appears logical,
it subjects approximately 20% of patients who will have a
<60% residual stenosis to an unnecessary procedure . The
ability to predict the residual stenosis in an infarct-related
artery after thrombolysis would be very useful in deciding
who should undergo catheterization . Several studies (10-13)
have provided evidence to suggest that patients with prein-
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antecedent angina, the group with antecedent angina had
an increased mean stenosis (74% versus 58%) and more
multivessel disease (44% versus 5%) .
The sensitivity and specificity of a clinical history of
antecedent angina predicting the presence of a significant
residual stenosis were 75% and  6%, respectively ; the
positive predictive accuracy was  8% . These data suggest
that antecedent angina can be used to identify a high risk
subgroup whose condition may warrant routine coronary
angiography .
(J Am Coll Cardiol 1 8  ;14  1-5)
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farction angina represent a subgroup who had severe steno-
sis of the infarct-related artery . Accordingly, we tested the
hypothesis that patients with a history of angina antedating
the onset of infarction were more likely than patients with no
antecedent angina to have a significant residual stenosis after
thrombolytic therapy .
Methods
Study patients . During the study period 1 86 to 1 88, 117
patients treated at University Hospital received throm-
bolytic therapy for an acute myocardial infarction . All
patients had ?30 min of chest pain consistent with myocar-
dial ischemia refractory to nitrate therapy and accompanied
by ST segment elevation in at least two contiguous electro-
cardiographic (ECG) leads . Excluded from consideration
were two patients who had previously undergone coronary
artery bypass grafting and one patient who had associated
critical aortic stenosis . Seventeen of the 117 patients were
treated with thrombolytic therapy but randomized to medi-
cal therapy as part of the Thrombolysis in Myocardial
Infarction (TIMI) study and therefore did not undergo cor-
onary angiography . Of the 100 patients who did undergo
coronary angiography, 82 patients did so as part of our
conventional follow-up to thrombolytic therapy before dis-
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charge and constitute our study group . The other 18 patients
who received thrombolytic therapy developed postinfarction
angina and therefore underwent urgent cardiac catheteriza-
tion. Although the results of their catheterizations are re-
ported, their data were excluded from statistical analysis
because the indication for catheterization was determined by
their unstable course .
Thrombolytic therapy . Treatment was administered in-
travenously within 6 h of onset of symptoms with either
recombinant tissue plasminogen activator (rt-PA), 150 mg
( 0 mg in the 1st h with a   mg bolus, 20 mg in the 2nd h and
10 mg in each of the next 4 h, n = 3); rt-PA, 100 mg (60 mg
in the 1st h with a 10 mg bolus, 20 mg in the 2nd h and 5 mg
in each of the next 4 h, n = 56) ; or streptokinase, 750,000 to
1,500,000 U (over I h, n = 23) .
Clinical variables . The presence or absence of a history
of angina before and not associated with the myocardial
infarction was determined in all patients by an attending
cardiologist or research nurse during the admission evalua-
tion or some time before catheterization . Antecedent angina
was defined as Canadian class I to IV angina occurring >24
h before the onset of myocardial infarction . Other data
including age, gender, cardiac risk factors, prior myocardial
infarction, time to thrombolytic therapy and time to coro-
nary angiography were recorded .
Coronary angiography. Coronary anatomy was inter-
preted by two angiographers unaware of the presence or
absence of a history of antecedent angina . The residual
stenosis in the infarct-related artery was evaluated at end-
diastole, in coaxial views when possible, and the mean
stenosis was obtained with use of electronic calipers. When
coaxial views were not available, the view that best demon-
strated the stenosis without foreshortening was used . A
significant stenosis was considered to be one of ?60%
diameter reduction. The presence of multivessel disease was
recorded and defined as a significant stenosis in two or more
major epicardial coronary arteries involving the territory of
the right, left anterior descending or left circumflex coronary
vessels. The presence or absence of coronary thrombus and
collateral vessels was recorded .
Statistical analysis . Groups of patients were compared
with use of chi-square analysis for categorical data and a
student t test for continuous data .
Results
Patient characteristics (Table 1). Forty-five patients had a
history of antecedent angina, whereas 37 did not . There were
no differences between the two groups in the clinical char-
acteristics evaluated . The time from onset of chest pain to
initiation of therapy and the time from hospital admission to
catheterization were similar as was the distribution of rt-PA
and streptokinase use .
Table 1 . Clinical Characteristics of 82 Patients
rt-PA = recombinant tissue-type plasminogen activator .
Residual coronary stenosis (Fig . 1) . The mean residual
stenosis was more severe in the patients with than in those
without a history of antecedent angina (74 .1 ± 11 .7% versus
58 .5 ± 21 .1%, p < 0 .001) . When all patients were stratified
according to a residual stenosis of <60% or >_60% diameter
reduction, a history of antecedent angina predicted a signif-
icant residual stenosis in most patients (positive predictive
accuracy =  8%) . The sensitivity and specificity for ante-
cedent angina identifying a significant residual stenosis were
75% and  6%, respectively .
Coronary angiography (Table 2). Multivessel disease was
more common in patients with than in patients without
antecedent angina (44% versus 5%, p < 0 .001) . Evidence of
an intraluminal filling defect at the site of the culprit lesion
consistent with thrombus was common in both groups (30%
versus 22%, p = NS) . Time from infarction to catheteriza-
tion did not differ statistically between the patients with and
without thrombus present (4 .1 days versus 2 .  days, p =
NS). Onset of angina in relation to the myocardial infarction
varied; pain began within 3 weeks in the majority of patients
(33 [75%] of 45) . Patients with chronic angina (present >3
Figure 1 . Percent stenosis in patients with antecedent angina and no
antecedent angina (mean ± SD) .
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Antecedent Angina
Present Absent
No. of patients
45 37
Male/female 33/12 23/14
Age (mean) (yr) 57 56
Time to thrombolytic therapy (h)
Mean 2 .5 2 .5
Range I to 5 1 to 6
Time to coronary angiography (days)
Mean 2 .8 3 .7
Range I to 10 1 to 11
Streptokinase treated (%) 27 32
rt-PA treated (%) 73 68
Diabetes mellitus (%) 11
8
Inferior myocardial infarction (%) 55 46
Cigarette smoking (%) 67 70
Prior myocardial infarction (%) 22 0 (p < 0 .01)
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Table 2 . Cornary Angiographic Characteristics in 82 Patients
weeks before infarction) were more likely to have multives-
sel disease (58% versus 3 %) and collateral vessels (25%
versus 17%) and were less likely to have thrombus present
(11% versus 3 %) at the time of angiography but these
findings did not attain statistical significance .
In
the subset of patients with a significant residual
stenosis, the incidence rate of collateral vessels was the
same (20%) in patients with and without antecedent angina .
Within this subset, the mean stenosis vessels was more
severe in patients with than in those without collateral
vessels ( 0.  ± 12.0 versus 70.5 ± 8.7, p < 0 .001) . Also
within this subset, the incidence of multivessel disease was
higher in patients with than in those without antecedent
angina (46% versus 13%, p = 0 .05). No patient with an
insignificant residual stenosis had collateral vessels .
Clinical characteristics of patients with insignificant versus
significant residual stenosis . The mean age, incidence of
diabetes mellitus and cigarette smoking, time to treatment
and thrombolytic agent used were similar in patients with a
significant or an insignificant (<60%) residual lesion (Table
3). Prior myocardial infarction and antecedent angina were
more common in patients with a significant residual stenosis
(17% versus 0%, p < 0 .1 and 75% versus 4%, p < 0 .001,
respectively) .
Postinfarction angina. The residual stenosis was ?80% in
17 of the 18 patients undergoing urgent catheterization
because of postinfarction angina .
Table 3 . Clinical Correlates of a Significant Residual Stenosis in
82 Patients
rt-PA = recombinant tissue-type plasminogen activator .
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Exercise stress testing . Low level exercise tests were
performed before discharge in 16 patients with no history of
antecedent angina and insignificant residual stenosis . Results
were negative in all 16 .
Discussion
Previous studies . Other investigators have shown that
patients with a significant residual coronary lesion after
thrombolytic therapy represent a high risk subgroup for
recurrent ischemia and reocclusion . Erbel et al . (2) reported
an overall 17% reocclusion rate and noted a more severe
residual stenosis in patients who exhibited reocclusion com-
pared with those who did not   87% versus 75% residual
stenosis, respectively . Surruys et al. (6) reported that 17 of
1  patients who exhibited reocclusion in their study had a
residual stenosis of >58% diameter reduction . Harrison et
al . (3) performed quantitative angiographic measurements of
the residual stenoses in 24 patients immediately after throm-
bolytic therapy and again at 8 to 14 days ; they found that
reocclusion occurred in 7 (56%) of 13 patients with a residual
lumen <0.4 mm but in no patients with a larger residual
lumen. In addition to placing the patient at increased risk for
reocclusion, a significant residual stenosis increases the
incidence of postinfarction ischemia (14) . When angioplasty
was performed to reduce the residual stenosis after throm-
bolysis, Guerci et al . (15) demonstrated a lower incidence of
recurrent ischemia and an improved exercise ejection frac-
tion . Although not yet supported by clinical data, animal
studies (16) also suggest that a critical residual stenosis
compromises perfusion and salvage of myocardium after
recanalization .
These findings have led to the practice of referring all
patients who receive thrombolytic therapy for routine car-
diac catheterization and angioplasty if a significant residual
lesion is present and the coronary anatomy is suitable for the
procedure. When the efficacy of this approach was tested in
the second phase of the Thrombolysis in Myocardial Infarc-
tion trial (TIMI 11) (17), the results did not demonstrate a
benefit over reserving catheterization and revascularization
for patients who demonstrate ischemia after thrombolysis .
The TIMI II trial supports our premise that routine cathe-
terization is not indicated in all patients, but it is not known
whether high risk subgroups exist that may benefit from an
aggressive approach . The present study supports our initial
hypothesis that patients with a history of angina before
infarction are more likely to have a hemodynamically signif-
icant residual stenosis after thrombolysis than are patients
with no antecedent angina. The findings suggest that a
clinical history of antecedent angina can be used to identify
a high risk subgroup .
Previous studies (10-13) of patients with a history of
preinfarction angina have documented a higher incidence of
subendocardial infarction and a higher residual left ventric-
Antecedent Angina
Present Absent
Multivessel disease (%) 44 5 p < 0 .001
Coronary thrombus (%) 30 22 p = NS
Collateral vessels (%) 20   p = NS
Percent Lesion
Stenosis
<60 60 to 100
Total no . 23
5 
No. with streptokinase
8 16
No. with rt-PA 15 43
Age (yr) 54 58
Time to treatment (h) 2 .5 2 .5
Diabetes mellitus (%) 5 12
Cigarette smoking (%) 77 67
Prior myocardial infarction (%) 0 17
p < 0
.1
Antecedent angina (%) 4
75 p < 0 .001
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ular ejection fraction secondary to the presence of well
developed collateral vessels . Because collateral vessels de-
velop only in response to a hemodynamically significant
stenosis, we expected to find significant lesions at angiogra-
phy in our patients with antecedent angina (10,18-20). Other
studies (21) have found that patients with a history of
antecedent angina have more postinfarction angina, suggest-
ing a critical culprit lesion . A significant residual stenosis
was present in 17 of the 18 patients in our study group who
underwent urgent catheterization for postinfarction angina .
Clinical presentation . In light of recent angiographic data
( ) establishing that an occlusive thrombus can form on a
mild to moderate underlying stenosis, it is not surprising that
some patients are free of angina before infarction. What
remains to be determined is the sequence of events that
converts a stable stenosis to an unstable one on which an
occlusive thrombus forms . Animal data (22,23) suggest that
de-endothelialization at the site of a stenosis leads to cyclic
platelet-mediated occlusions initially, and, if the process is
uninterrupted, rapidly leads to an occlusive thrombus . We
defined antecedent angina as angina occurring ?24 h before
infarction in order to exclude patients whose pain in the
early hours before infarction represented a stuttering infarc-
tion rather than a severe underlying stenosis . Most (84%) of
our patients with antecedent angina had pain >48 h before
infarction. We purposely included patients with unstable
angina of recent onset, realizing that some of the mechanical
stenosis in their lesion may represent organized thrombus
that was several days old (24,25) . Thrombolytic agents,
especially streptokinase, are less effective in dissolving
thrombus that is old and therefore likely to remain a com-
ponent of the residual stenosis (26) .
Limitations . The sensitivity, specificity and predictive
value in our study suggest a strong correlation between
antecedent angina and a significant residual stenosis . How-
ever, we studied a relatively small number of patients .
Clearly confounding variables of silent ischemia, coronary
spasm and multivessel disease would be expected to de-
crease the predictive value of antecedent angina in a larger
study population . The inability of antecedent angina to
identify all patients with a significant residual stenosis is also
a limitation . Of note, patients with a significant residual
stenosis and no antecedent angina had a lesser incidence of
prior myocardial infarction (0% versus 31%, p = 0 .04) and
less multivessel disease than did patients with a significant
stenosis and antecedent angina (13% versus 46%, p = 0 .05) .
At present, there is no other clinical characteristic known to
predict residual stenosis ; thus, the results of this study
provide new information that is useful when deciding which
patients should undergo angiography after thrombolytic
therapy .
Clinical implications . In summary, the results of this
study, performed in 82 patients who underwent routine
coronary angiography after thrombolytic therapy for an
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acute myocardial infarction, support our initial hypothesis
that patients with a history of antecedent angina are more
likely to have a hemodynamically significant residual steno-
sis than are patients without prior angina . There is also a
significant correlation between antecedent angina and mul-
tivessel disease . These data suggest that a clinical history of
antecedent angina identifies a subgroup of patients at an
increased risk for subsequent ischemic events . Whether
routine catheterization and appropriate revascularization
favorably influence their course needs to be explored .
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